UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and a prostate-specific antigen doubling time (PSADT) >6 months

European urology open science (Online), 2020-07, Vol.19, p.e1389-e1390

2020

Volltextzugriff (PDF)

Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials

JAMA : the journal of the American Medical Association, 2012-03, Vol.307 (11), p.1151

2012

Volltextzugriff (PDF)

Clinical benefit and safety profile of darolutamide in patients who crossed over to darolutamide from placebo during the open-label period of the phase 3 ARAMIS study

European urology, 2021-06, Vol.79, p.S1742-S1743

2021

Volltextzugriff (PDF)

The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure

International journal of clinical pharmacology and therapeutics, 2008-08, Vol.46 (8), p.389

2008

Volltextzugriff (PDF)

Hormone treatment–related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAMIS study

European urology, 2021-06, Vol.79, p.S1740-S1741

2021

Volltextzugriff (PDF)

223P Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

Annals of oncology, 2020-11, Vol.31, p.S1328-S1328

2020

Volltextzugriff (PDF)

OP01-1 - Preoperative treatment with levosimendan in CABG surgery: data from the LEVO-CTS and LICORN studies

Journal of cardiothoracic and vascular anesthesia, 2018-08, Vol.32, p.S21-S22

2018

Volltextzugriff (PDF)

Preoperative treatment with levosimendan in CABG surgery: data from the LEVO-CTS and LICORN studies

Journal of cardiothoracic and vascular anesthesia, 2018-08, Vol.32, p.S21-S22

2018

Volltextzugriff (PDF)

Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial

Annals of oncology, 2019-11, Vol.30, p.ix69

2019

Volltextzugriff (PDF)

Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy

International journal of cardiology, 2017-09, Vol.243, p.389-395

2017

Volltextzugriff (PDF)

Effect of Sedation Regimen on Weaning from Mechanical Ventilation in the Intensive Care Unit

Clinical drug investigation, 2018-06, Vol.38 (6), p.535-543

2018

Volltextzugriff (PDF)

Dexmedetomidine versus propofol/midazolam for long-term sedation during mechanical ventilation

Intensive care medicine, 2009-02, Vol.35 (2), p.282-290

2009

Volltextzugriff (PDF)

Darolutamide in nonmetastatic, castration-resistant prostate cancer

Yearbook of Paediatric Endocrinology, 2019-09

2019

Volltextzugriff (PDF)

567 Safety and antitumor activity of ODM-201 in chemotherapy and CYP17-inhibitor naïve patients from the ARADES and the ARAFOR trials

European urology supplements : official journal of the European Association of Urology, 2015-04, Vol.14 (2), p.e567-e567

2015

Volltextzugriff (PDF)

The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II

International journal of clinical pharmacology and therapeutics, 2008-08, Vol.46 (8), p.389-399

2008

Volltextzugriff (PDF)

Effect of levosimendan treatment on length of hospital and intensive care stay in the REVIVE I study

Critical care (London, England), 2004, Vol.8 Suppl 1 (Suppl 1), p.P88-P88

2004

Volltextzugriff (PDF)

Comparison of the effect of concomitant beta-blocking treatment on the symptomatic responses to levosimendan and dobutamine in patients with severe low-output heart failure

Journal of cardiac failure, 2004-08, Vol.10 (4), p.S120-S120

2004

Volltextzugriff (PDF)

449 Levosimendan reduces mortality when compared with dobutamine in patients receiving beta blockers

European journal of heart failure. Supplements, 2007-06, Vol.6 (Suppl), p.95-95

2007

Volltextzugriff (PDF)

Study design of a mortality trial with intravenous levosimendan (the SURVIVE study) in patients with acutely decompensated heart failure

Critical care (London, England), 2004, Vol.8 Suppl 1 (Suppl 1), p.P87-P87

2004

Volltextzugriff (PDF)

Study design of a mortality trial with intravenous levosimendan - the SURVIVE study - in patients with acutely decompensated heart failure

Journal of cardiac failure, 2004-08, Vol.10 (4), p.S81-S81

2004

Volltextzugriff (PDF)

272 Oral antidiabetics do not attenuate the efficacy of levosimendan

European journal of heart failure. Supplements, 2004-06, Vol.3 (Suppl), p.65-65

2004

Volltextzugriff (PDF)

341 A meta-analysis on the safety of the calcium sensitizing agent levosimendan

European journal of heart failure. Supplements, 2004-06, Vol.3 (Suppl), p.86-86

2004

Volltextzugriff (PDF)

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

The New England journal of medicine, 2019-03, Vol.380 (13), p.1235-1246

2019

Volltextzugriff (PDF)

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide

The New England journal of medicine, 2020-09, Vol.383 (11), p.1040-1049

2020

Volltextzugriff (PDF)

Effect of Levosimendan on the Short-Term Clinical Course of Patients With Acutely Decompensated Heart Failure

JACC. Heart failure, 2013-04, Vol.1 (2), p.103-111

2013

Volltextzugriff (PDF)

1 – 25 von 62

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(57)
Mit Volltextzugriff
(52)

Publikationsform

Artikel
(62)

Sprache

Englisch
(62)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(27)
Science & Technology
(27)
Humans
(20)
Male
(15)
Double-Blind Method
(12)
Aged
(11)
Middle Aged
(11)
Female
(10)
Cardiac & Cardiovascular Systems
(7)
Cardiovascular System & Cardiology
(7)
Heart Failure - Drug Therapy
(7)
Clinical Trials
(6)
General & Internal Medicine
(6)
Oncology
(6)
Patients
(6)
Darolutamide
(5)
Hydrazones - Administration & Dosage
(5)
Levosimendan
(5)
Medicine
(5)
Prostate Cancer
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and a prostate-specific antigen doubling time (PSADT) >6 months

Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials

Clinical benefit and safety profile of darolutamide in patients who crossed over to darolutamide from placebo during the open-label period of the phase 3 ARAMIS study

The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure

Hormone treatment–related adverse events (HTR AEs) with darolutamide (DARO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from the phase 3 ARAMIS study

223P Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

OP01-1 - Preoperative treatment with levosimendan in CABG surgery: data from the LEVO-CTS and LICORN studies

Preoperative treatment with levosimendan in CABG surgery: data from the LEVO-CTS and LICORN studies

Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial

Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy

Effect of Sedation Regimen on Weaning from Mechanical Ventilation in the Intensive Care Unit

Dexmedetomidine versus propofol/midazolam for long-term sedation during mechanical ventilation

Darolutamide in nonmetastatic, castration-resistant prostate cancer

567 Safety and antitumor activity of ODM-201 in chemotherapy and CYP17-inhibitor naïve patients from the ARADES and the ARAFOR trials

The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II

Effect of levosimendan treatment on length of hospital and intensive care stay in the REVIVE I study

Comparison of the effect of concomitant beta-blocking treatment on the symptomatic responses to levosimendan and dobutamine in patients with severe low-output heart failure

449 Levosimendan reduces mortality when compared with dobutamine in patients receiving beta blockers

Study design of a mortality trial with intravenous levosimendan (the SURVIVE study) in patients with acutely decompensated heart failure

Study design of a mortality trial with intravenous levosimendan - the SURVIVE study - in patients with acutely decompensated heart failure

272 Oral antidiabetics do not attenuate the efficacy of levosimendan

341 A meta-analysis on the safety of the calcium sensitizing agent levosimendan

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide

Effect of Levosimendan on the Short-Term Clinical Course of Patients With Acutely Decompensated Heart Failure

Suchergebnisse filtern